BMP6 and plasma cell myeloma: Consistent with this, we found treatment of human JJN-3 and murine 5TGM1 myeloma cells with recombinant human BMP6 induced a dose-dependent reduction in myeloma cell viability (Fig. 2h) that was rescued in both cell lines by treatment with LDN (Fig. 2i).